(RTTNews) - Kezar Life Sciences, Inc. (KZR), a clinical-stage biotechnology company, Monday announced one-for-ten reverse stock split.
This reverse stock split is to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market.
The company's shares will trade on a post-split basis beginning on October 30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
